396 related articles for article (PubMed ID: 15717742)
21. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
22. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
23. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
24. Managing cardiotoxicity in anthracycline-treated breast cancers.
Ng R; Green MD
Expert Opin Drug Saf; 2007 May; 6(3):315-21. PubMed ID: 17480180
[TBL] [Abstract][Full Text] [Related]
25. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.
Gabizon AA; Lyass O; Berry GJ; Wildgust M
Cancer Invest; 2004; 22(5):663-9. PubMed ID: 15581046
[TBL] [Abstract][Full Text] [Related]
26. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma.
Pratt G; Wiles ME; Rawstron AC; Davies FE; Fenton JA; Proffitt JA; Child JA; Smith GM; Morgan GJ
Hematol Oncol; 1998 Jun; 16(2):47-55. PubMed ID: 10065112
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
28. Current status of liposomal anthracycline therapy in metastatic breast cancer.
Rivera E
Clin Breast Cancer; 2003 Nov; 4 Suppl 2():S76-83. PubMed ID: 14667278
[TBL] [Abstract][Full Text] [Related]
29. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer.
Campos S
Oncologist; 2003; 8 Suppl 2():10-6. PubMed ID: 13679591
[TBL] [Abstract][Full Text] [Related]
30. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
31. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
32. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG
Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266
[TBL] [Abstract][Full Text] [Related]
33. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
34. [Prevention of anthracycline cardiotoxicity].
Rossetti R
Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
[No Abstract] [Full Text] [Related]
35. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
36. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
37. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
38. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Curtit E; Nouyrigat P; Dohollou N; Levy E; Lortholary A; Gligorov J; Facchini T; Jaubert D; Maille N; Pivot X; Grangé V; Cals L
Eur J Cancer; 2011 Nov; 47(16):2396-402. PubMed ID: 21920729
[TBL] [Abstract][Full Text] [Related]
39. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
40. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Kremer LC
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]